A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Protocol No
JNJ-68284528MMY3004CARTITUDE-5
Phase
III
Summary

The purpose of this study is to see if VRd followed by cilta-cel is safe and useful for treating
patients with newly diagnosed Multiple Myeloma, as compared with the use of VRd followed by Rd therapy.

Description
CAR-T Clinical trial in Subjects with Newly Diagnosed MM and for Whom HSCT is not planned
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL